Rentschler Biotechnologie GmbH & Co. Appoints New Chief Business Officer

Published: Mar 07, 2013

Laupheim, Germany, March 7, 2013 / B3C newswire / - Rentschler Biotechnologie GmbH, a leading contract manufacturing organization for the development and production of biopharmaceuticals, today announced the appointment of Frank Ternes to the position of Chief Business Officer effective February 1, 2013. In this position, Mr. Ternes will contribute to the success of the organization by leading the planning, development and execution of all business development, sales & marketing and project management activities.

"Mr. Ternes is an excellent addition to Rentschler's management board," says Dr. Nikolaus F. Rentschler, CEO and owner of Rentschler. "With his broad experience in the contract manufacturing business, he has a keen understanding of technology, a strong customer focus, and a proven track record for achieving success.”

Frank Ternes brings more than 25 years of experience from Operations and Technology at Boehringer Ingelheim where he last served as Senior Vice President of Biopharmaceutical Contract Manufacturing.

Mr. Ternes holds a degree equivalent to a master’s degree in economics from the University of Bonn, Germany.

About Rentschler

Rentschler Biotechnologie GmbH is a global full-service contract manufacturer with more than 35 years of experience in the development, production and approval of biopharmaceuticals in compliance with international GMP standards (EMA/FDA). Rentschler has nine GMP suites with volumes of 30, 50, 250, 500, 1,000 and 2,500 liters, allowing the production of material for clinical trials (phases I to III) and for market supply and also provides regulatory advice, protein analytics, quality control, and the sterile filling of syringes and injection vials. The company is family-owned and independent and has currently about 650 employees.


Friederike Braun

Director Marketing

Rentschler Biotechnologie GmbH

Phone: +49 7392 701-478

Back to news